Solid Biosciences shares surge 13.37% after-hours after providing 2026 outlook highlighting pipeline momentum and next-gen capsid access.

Solid Biosciences (SLDB) surged 13.37% in after-hours trading following a series of positive developments. The company announced it received FDA Orphan Drug Designation for SGT-212, a dual-route gene therapy for Friedreich’s Ataxia, and dosed the first participant in its Phase 1b FALCON trial evaluating the same therapy. Additionally, Solid Biosciences highlighted its 2026 pipeline outlook, emphasizing momentum in neuromuscular and cardiac therapies, including its next-generation capsid AAV-SLB101. These updates, coupled with recent licensing agreements and expanded access initiatives, reinforced investor confidence in the company’s therapeutic advancements. The stock’s sharp rise aligns with regulatory and clinical milestones, which are critical drivers for biotech firms in early-stage gene therapy development.